Drug Profile

TYRA 430

Alternative Names: TYRA-430

Latest Information Update: 21 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tyra Biosciences
Class Antineoplastics; Small molecules
Mechanism of Action Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 May 2025 Phase-I clinical trials in Liver cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO) (NCT06915753)
01 May 2025 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO) (NCT06915753)
10 Apr 2025 Phase-I clinical trials in Liver cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06915753)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com